To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis
Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
A Minimum of 150 consecutive patients of decompensated cirrhosis of any etiology, presenting
to the Institute of Liver and Biliary Sciences hospital with a diagnosis of difficult to
treat SBP will be included and randomized into two treatment groups.
Group A - Carbepenem+albumin Group B - Carbepenem+albumin+GMCSF.